Pegfilgrastim
Systematic (IUPAC) name | |
---|---|
N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene) | |
Clinical data | |
Trade names | originally Neulasta, other brand names worldwide[1] |
AHFS/Drugs.com | monograph |
MedlinePlus | a607058 |
Pregnancy category |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Biological half-life | 15–80 hrs |
Identifiers | |
CAS Number | 208265-92-3 |
ATC code | L03AA13 (WHO) |
IUPHAR/BPS | 6969 |
DrugBank | DB00019 |
ChemSpider | none |
UNII | 3A58010674 |
KEGG | D06889 |
ChEMBL | CHEMBL1201568 |
Chemical data | |
Formula | C845H1343N223O243S9 + PEG |
Molar mass | 39,000 g/mol |
(what is this?) (verify) |
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[2]
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]
Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[4][3]
See also
References
- ↑ Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
- ↑ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–137.
- 1 2 Drugs.com: Pegfilgrastim
- ↑ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, p. 139, 158.
External links
- Neulasta
- Neulasta full prescribing information
- Neulasta Onpro kit Healthcare Provider Instructions for Use
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.